Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?
Executive Summary
Sales of the insulin glargine product in its first full year on the market were strong at $432.1m, but Lilly said it is offering steep rebates in exchange for market access and it's not clear that the growth is sustainable if more copies enter the market.
You may also be interested in...
Basaglar Saved Medicaid Millions, Highlighting Benefits Of Competition, JAMA Analysis Shows
Researchers analyzed usage rates, market share and reimbursement information for the long-acting insulins Lantus and Basaglar to determine the impact from the launch of Lilly’s long-acting Basaglar.
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
As pharma invests its bounty from last year's tax reform in stock buybacks, capital improvements and other investments, Sen. Cory Booker issues a report suggesting companies should lower drug prices instead, but does not offer recommendations for how that might be done.
Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017
Express Scripts' annual drug trend report highlights impact of key follow-on launches, and its own management solutions programs, in limiting the growth in overall drug spending for commercial plans to 1.5%; forecast calls for double-digit growth in inflammatory category to continue at least the next three years until biosimilar savings kick in.